Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

LncRNA profile of human liver tissues: hepatocellular carcinoma vs. matched noncancerous liver tissue

ABSTRACT: LncRNA profiling of hepatocellular carcinoma vs. matched noncancerous liver tissue, aimed to analyze the lncRNA expression proﬁle of hepatocellular carcinoma (HCC) and identify prognosis-related lncRNAs.

ORGANISM(S): Homo sapiens

PROVIDER: GSE72170 | GEO | 2023/06/25

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

microRNA profile of human liver tissues: hepatocellular carcinoma vs. matched noncancerous liver tissue

Project description:microRNA profiling of hepatocellular carcinoma vs. matched noncancerous liver tissue 166 pairs of hepatocellular carcinoma and matched noncancerous liver tissues

2011-08-15 | E-GEOD-31384 | biostudies-arrayexpress

microRNA profile of human liver tissues: hepatocellular carcinoma vs. matched noncancerous liver tissue

Project description:microRNA profiling of hepatocellular carcinoma vs. matched noncancerous liver tissue

2011-08-16 | GSE31384 | GEO

hepatocellular carcinoma vs. corresponding noncancerous liver or normal liver

Project description:Hepatocellular carcinoma (HCC) remains a major health problem worldwide, and HCC patients have a poor prognostic outcome. In this study, we systematically disclose mechanisms of hepatocarcinogenesis, and also effectively identify and validate novel anticancer targets in HCCs. Keywords: disease state analysis total 58 cDNA microarrays, all experiment samples are hepatocellular carcinoma. RNAs from 33 corresponding noncancerous livers and 5 normal livers were used as the reference, respectively. The tumor samples were labeled with Cy5-dUTP.The nontumor samples were labeled with Cy3-dUTP.

2009-01-06 | E-GEOD-4108 | biostudies-arrayexpress

Transcriptional profile of human liver tissues: hepatocellular carcinoma vs. matched noncancerousliver tissue

Project description:Transcriptional profiling of hepatocellular carcinoma vs. matched noncancerous liver tissue

2011-02-12 | GSE27150 | GEO

Transcriptional profile of human liver tissues: hepatocellular carcinoma vs. matched noncancerousliver tissue

Project description:Transcriptional profiling of hepatocellular carcinoma vs. matched noncancerous liver tissue 81 pairs of hepatocellular carcinoma and matched noncancerousliver tissues

2011-02-12 | E-GEOD-27150 | biostudies-arrayexpress

hepatocellular carcinoma vs. corresponding noncancerous liver or normal liver

2009-01-06 | GSE4108 | GEO

LncRNA expression profile in gastric cancer specimens and adjacent noncancerous tissues

Project description:We implemented lncRNA microarray analysis in 5 paired gastric cancer tissues and adjacent noncancerous tissues to identify differential expression of lncRNAs and mRNAs in gastric cancer.

2021-04-14 | GSE157289 | GEO

Genotyping by array of hepatocellular carcinoma tumors and their matched noncancerous liver tissues and the background germline

Project description:We performed whole-genome sequencing and ploidy profiling on multiple tumors and their matched noncancerous liver tissues and the background germline. We found that the noncancerous liver tissues presented varying degrees of genomic alterations that were associated with the background liver diseases. Most of the genomic alterations in the metastatic tumors were inherited from the primary tumor and a small number developed de novo. Few genomic alterations were shared between the multicentric tumors with the exception of the alterations that also existed in the noncancerous liver tissue. The findings revealed the molecular mechanisms of intra-individual tumor evolution and may facilitate the determination of appropriate clinical management strategies and the identification of novel therapeutic targets.

2014-06-06 | E-MEXP-3705 | biostudies-arrayexpress

Low SLC22A7 expression in noncancerous liver promotes hepatocellular carcinoma occurrence - a prospective study

Project description:Background & Aims: The recurrence determines the postoperative prognosis of patients with hepatocellular carcinoma (HCC). It is unknown whether de novo HCCs derive from the liver with disability of an organic anion transport. This study was designed to elucidate the link between such transporters and the multicentric occurrence (MO) after radical hepatectomy. Results: SLC22A7 expression was the best predictor of metastasis-free survival (MFS) as judged by the GA (Fold, 0.726; P=0.001). High SLC22A7 gene expression in noncancerous tissue prevent HCC occurrence after hepatectomy (Odds Ratio (OR), 0.2; 95%CI, 0.1-0.6; P=0.004). Multivariate analyses of MFS revealed the independent risk factor to be SLC22A7 expression (OR, 0.3; 95%CI, 0.1-1.0, P=0.043). Low SLC22A7 expression caused MO of HCC significantly (log-rank, P=0.001). In the validation study, multivariate analyses of MFS revealed the independent risk factor to be SLC22A7 expression (OR, 0.5; 95%CI, 0.3-0.8; P=0.012). As judged by Gene set-enrichment analysis, SLC22A7 down-regulation associated with mitochondrion (P=0.008; false discovery rate (FDR)=0.199; normalized enrichment score (NES) =1.804), oxidoreductase activity (P=0.006; FDR=0.157; NES=1.854) and fatty acid metabolic process (P=0.021; FDR=0.177; NES=1.723). Sirtuin3 also determined MFS (P= 0.018). Conclusions: These pathways involving SLC22A7 dysfunction may promote the occurrence of HCC. The 49 noncancerous liver tissues of HCC patients within Milan criteria, treated at our institution between January 2004 and August 2008, were examined as a training set by genome-wide gene expression analysis (GA). Cox proportional hazards regression analyses for MO-free survival (MFS) were performed to estimate the risk factors. Using the independent two institutional cohorts of 134 patients between September 2008 and December 2009, a validation study was employed using tissue microarrays.

2013-04-01 | E-GEOD-40873 | biostudies-arrayexpress

Superenhancer-driven lncRNA FASRL in hepatocellular carcinoma

Project description:Superenhancer-driven lncRNA FASRL in hepatocellular carcinoma

| PRJNA851360 | ENA